Right now, there’s a company that’s developed a pharmaceutical-based treatment that could allow you to not only live a longer life, but do so in a way that would allow you to never have to worry about getting any age-related chronic diseases. And it's public.

Change happens. And while change can be hard for some folks to accept, it shouldn’t be hard to profit from. Energy and Capital editor Jeff Siegel discusses some upcoming change in the biotech sector and how investors can profit...

Today, Energy and Capital editor Jeff Siegel is simply going to share with you three reports that focus on a handful of companies that are already proving to be COVID-resistant...

Some have called it the most undervalued stock in the biotech space. Energy and Capital editor Jeff Siegel profiles a stock that has developed an anti-aging pill that could change humanity as we know it...

Energy and Capital editor Jeff Siegel is very bullish right now on a small biotech firm that’s currently conducting clinical trials on a new drug that looks like it could not only completely cure chronic diseases, but even reverse them...

Doctors from biotech firm Verve Therapeutics have developed a new gene-editing serum that switches off the genes that regulate both LDL cholesterol and triglycerides.  Energy and Capital editor Jeff Siegel explains how investors can take advantage...